22 results about "Macular Pigment" patented technology

An ocular fundus image processing device acquires a first image generated by irradiating an ocular fundus of a subject with excitation light of a blue wavelength and a second image generated by irradiating the ocular fundus with excitation light of a green wavelength, generates three trained models for predicting a correction factor for calculating a quantity of macular pigment of the subject from input images including the first image and the second image through training using three different initial values, predicts three correction factors by inputting the input images including the first image and the second image to the three trained models, calculates a statistical value of the three correction factors and derives the statistical value as the correction factor of the subject, and calculates a quantity of macular pigment of the subject on the basis of the first image and the correction factor of the subject.

A system and method are provided for bimodal detection and / or imaging of macular pigments. Fundus autofluorescence spectroscopy is applied in a first and a second region of an eye to measure fluorescence values from the fluorescing pigment (e.g., lipofuscin). The first region can be a macula, which has a higher density of macular pigments, and the second region can be in the peripheral retina, which has a lower density of macular pigments. Fundus reflection spectroscopy is applied in the first and a second region of an eye, as a baseline image, to determine absorptions due to other pigments (e.g., melanin) than the macular pigments and the fluorescing pigment. The density of macular pigments is determined using the measures fluorescence values and the absorptions due to other pigments.

Described is an ophthalmic device that contains visible light filters. The ophthalmic device is a free radical reaction product of a reactive mixture comprising: one or more monomers suitable for making the ophthalmic device; a first visible light filtering compound, the first visible light filtering compound having a visible light absorption maximum between 430 and 480 nm and a full width half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and up to 150 nanometers, wherein the compound is photostable, and wherein the compound has a molar extinction coefficient of at least 7740 L·mol−1·cm−1; and a second visible light filtering compound. The devices may provide one or more benefits to wearers, including enhanced macular pigment optical density (MPOD), as well as improved color perception and color enhancement.

Described is an ophthalmic device that contains visible light filters. The invention provides an ophthalmic device that is a free radical reaction product of a reactive mixture comprising: one or more monomers suitable for making the ophthalmic device; a first visible light filtering compound, the first visible light filtering compound having a visible light absorption maximum between 430 and 480 nm and a full width half maximum at the visible light absorption maximum of at least 35 nm and up to 150 nanometers, wherein the first visible light filtering compound is photostable, and wherein the first visible light filtering compound has a molar extinction coefficient of at least 7740 L·mol−1·cm−1; and a second visible light filtering compound having a visible light absorption maximum between 480 and 530 nm and a full width half maximum of at least 50 nanometers and up to 150 nanometers. The reactive monomer mixture may also contain a third visible light filtering compound. The devices may provide one or more vision benefits, including enhanced macular pigment optical density as well as improved color perception and color enhancement and diminished visual artifacts.

Carotenoid compositions are described for management, treatment, and / or prevention of stress by reducing cortisol levels and / or improving distribution and / or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005 mg / kg body weight of lutein, and at least or about 0.001 mg / kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and / or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.

An ocular fundus image processing apparatus (1) includes: an image input unit (3) that acquires a first ocular fundus image generated by irradiating an ocular fundus of a subject with excitation light of a blue wavelength and a second ocular fundus image generated by irradiating the ocular fundus of the subject with excitation light of a green wavelength; a model generation unit (7) that generates three completed learning models for predicting correction coefficients for calculating a macular pigment amount of the subject from input images including the first ocular fundus image and the second ocular fundus image by training using three different initial values; a coefficient prediction unit (9) that predicts three correction coefficients by inputting the input images including the first ocular fundus image and the second ocular fundus image to the three completed learning models; a coefficient derivation unit (11) that calculates a statistical value using the three correction coefficients as a target and derives the correction coefficients of the subject as a statistical value; and a pigment amount calculation unit (13) that calculates the macular pigment amount of the subject based on the first ocular fundus image and the correction coefficients of the subject.

The application discloses a macular pigment optical density analysis method and system based on multispectral imaging and deep learning and a storage medium. The method comprises the following steps: collecting multispectral fundus images of a human eye retina under narrow-band wavelengths and performing registration; automatically segmenting a macular region and a foveal region by using a pre-trained deep learning segmentation model; extracting multispectral features from the segmented region; inputting the features into a deep regression model with physical information constraints to output the macular pigment optical density values of each position; and finally generating an MPOD spatial distribution map and performing visualization. The application innovatively introduces a physical information constraint neural network, integrates the Beer-Lambert law as a physical loss term into model training, significantly improves the accuracy, robustness, interpretability and device independence of MPOD quantification, overcomes the technical defects of existing subjective methods and traditional optical imaging methods, and can provide a powerful tool for ophthalmic disease screening and monitoring.

An ophthalmic device comprising a visible light filter is described. The ophthalmic device is a free radical reaction product of a reactive mixture comprising: one or more monomers suitable for making the ophthalmic device; a first visible light filtering compound having a visible light absorption maximum between 430 nm and 480 nm and having a full width at half maximum (FWHM) of at least 35 nm and at most 150 nm at the visible light absorption maximum, where the compound is light stable, and where the compound has a molar extinction coefficient of at least 7740 L.mol <-1 >. Cm <-1 >; and a second visible light filtering compound. The device may provide one or more benefits to the wearer, including enhanced macular pigment optical density (MPOD) as well as improved color perception and color enhancement.

This invention introduces an improved method for measuring macular pigment optical density (MPOD) using autofluorescence imaging (AFI). Traditional AFI methods often neglect melanin absorption, leading to inaccuracies. The proposed method employs three wavelengths: 488 nm for the main image, 514 nm as a traditional baseline, and 600 nm as an additional baseline to account for melanin absorption. By converting the melanin absorption coefficient from 600 nm to 488 nm and 514 nm, this method ensures precise MPOD measurements. Additionally, a simplified dual-wavelength method is introduced using 488 nm and 600 nm for scenarios requiring less complexity. Both approaches enhance the accuracy of non-invasive retinal imaging by providing a more reliable tool for assessing macular pigment levels and improving our understanding of retinal health.

An instrument includes a housing with a lower hand-held portion having a user-input button and a display for displaying an MPOD score for the user. The instrument further includes a viewing tube coupled to the hand-held portion. The viewing tube terminates in an eye cup. The viewing tube is transverse to the lower hand-held portion and transmits light from a first light source towards a reflector and is reflected off the reflector through an aperture in a blocking wall and in a direction toward the macula. The first light source is an LED and provides two colored lights alternating at a frequency to create a flicker. The frequency is used to determine an amount of macular pigment of the macula of the user. A second light source is located in the first portion of the viewing tube and configured to illuminate a surface of the blocking wall.

Described are visible light absorbing compounds. The compounds have a visible light absorption maximum between 430 and 480 nm and a full width half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and up to 100 nanometers, wherein the compounds are photostable. The compounds substantially mimic the visible light absorbance properties of macular pigment while remaining photostable. The compounds may be used in a variety of articles, including ophthalmic devices.

This invention introduces an improved method for measuring macular pigment optical density (MPOD) using autofluorescence imaging (AFI). Traditional AFI methods often neglect melanin absorption, leading to inaccuracies. The proposed method employs three wavelengths: 488 nm for the main image, 514 nm as a traditional baseline, and 600 nm as an additional baseline to account for melanin absorption. By converting the melanin absorption coefficient from 600 nm to 488 nm and 514 nm, this method ensures precise MPOD measurements. Additionally, a simplified dual-wavelength method is introduced using 488 nm and 600 nm for scenarios requiring less complexity. Both approaches enhance the accuracy of non-invasive retinal imaging by providing a more reliable tool for assessing macular pigment levels and improving our understanding of retinal health.

The invention relates to a macular pigment density calculation method and device, electronic equipment and a storage medium, and the method comprises the steps: obtaining a to-be-processed fundus image and historical fundus images, the historical fundus images being at least one fundus image of a shooting object of the to-be-processed fundus image in a past preset time period; determining an illumination component of the fundus image to be processed and an illumination component of the historical fundus image, and determining an average value of the illumination component of the historical fundus image to obtain a reference illumination component; correcting the illumination component of the eye fundus image to be processed based on the reference illumination component to obtain a corrected image; and according to the corrected image, determining a target macular pigment density corresponding to the eye fundus image to be processed. The problems of unstable quality and inconsistent brightness or chromaticity of the fundus image caused by different shooting conditions can be avoided, so that the corrected image can more truly reflect the current eye lesion condition of the shot object, and the real macular pigment density level of a photographer can be more reliably evaluated.

A system and method are provided for bimodal detection and / or imaging of macular pigments. Fundus autofluorescence spectroscopy is applied in a first and a second region of an eye to measure fluorescence values from the fluorescing pigment (e.g., lipofuscin). The first region can be a macula, which has a higher density of macular pigments, and the second region can be in the peripheral retina, which has a lower density of macular pigments. Fundus reflection spectroscopy is applied in the first and a second region of an eye, as a baseline image, to determine absorptions due to other pigments (e.g., melanin) than the macular pigments and the fluorescing pigment. The density of macular pigments is determined using the measures fluorescence values and the absorptions due to other pigments.

The invention discloses a macular pigment density analysis method and system based on multispectral imaging and deep learning, and a storage medium. The method comprises the following steps: acquiring a multispectral fundus image of a human eye retina under a narrow-band wavelength and performing registration; automatically segmenting a macular region and a concave center region by using a pre-trained deep learning segmentation model; extracting multispectral features from the segmented regions; inputting the features into a physical information constrained depth regression model, and outputting the macular pigment optical density value of each position; and finally, generating an MPOD spatial distribution map and carrying out visualization. According to the method, the physical information constraint neural network is innovatively introduced, the Beer-Lambert law is used as a physical loss item to be fused into model training, the precision, robustness, interpretability and equipment independence of MPOD quantization are remarkably improved, the technical defects of an existing subjective method and a traditional optical imaging method are overcome, and the method is suitable for popularization and application. And a powerful tool can be provided for screening and monitoring ophthalmic diseases.

Described is an ophthalmic device that contains visible light filters. The invention provides an ophthalmic device that is a free radical reaction product of a reactive mixture comprising: one or more monomers suitable for making the ophthalmic device; a first visible light filtering compound, the first visible light filtering compound having a visible light absorption maximum between 430 and 480 nm and a full width half maximum at the visible light absorption maximum of at least 35 nm and up to 150 nanometers, wherein the first visible light filtering compound is photostable, and wherein the first visible light filtering compound has a molar extinction coefficient of at least 7740 L.mol-1.cm-1; and a second visible light filtering compound having a visible light absorption maximum between 480 and 530 nm and a full width half maximum of at least 50 nanometers and up to 150 nanometers. The reactive monomer mixture may also contain a third visible light filtering compound. The devices may provide one or more vision benefits, including enhanced macular pigment optical density as well as improved color perception and color enhancement and diminished visual artifacts.

An ophthalmic device containing a visible light filter is described. The present invention provides an ophthalmic device that is the product of a free radical reaction of a reactive mixture comprising: one or more monomers suitable for manufacturing ophthalmic devices; a first visible light filter compound having a maximum visible light absorption between 430 nm and 480 nm and a full width at half maximum (FWHM) of at least 35 nm and at most 150 nm at the maximum visible light absorption, wherein the first visible light filter compound is photostable, and wherein the first visible light filter compound has a concentration of at least 7740 L·mol⁻¹. ‑1 .cm ‑1 The device contains a molar extinction coefficient and a second visible light filter compound having a maximum visible light absorption between 480 nm and 530 nm and a full width at half maximum (FWHM) of at least 50 nm and at most 150 nm. The reactive monomer mixture may also contain a third visible light filter compound. These devices can provide one or more visually beneficial effects, including enhanced macular pigment optical density, improved color perception and color enhancement, and reduced visual artifacts.

The present invention relates to methods for measuring macular pigment optical density (MPOD) more accurately by accounting for melanin absorption. Traditional heterochromatic flicker photometry (HFP) techniques do not consider melanin, leading to inaccuracies. This patent introduces two novel methods to correct for melanin absorption: (1) adding an additional LED wavelength around 600 nm that is absorbed by melanin but not by macular pigment, and (2) replacing the green LED in the traditional HFP setup with a red LED that is absorbed by melanin but not by macular pigment. These methods improve the accuracy of MPOD measurements, providing more reliable data for clinical and research applications.

The present invention describes a visible light absorbing compound. The compound has a visible light absorption maximum between 430 nm and 480 nm and a maximum full width at half maximum (FWHM) of at least 35 nm and at most 150 nm at the visible light absorption maximum, wherein the compound is photostable. The compound is also thermostable. The compound substantially mimics the visible light absorption characteristics of macular pigment while maintaining photostability and thermostability. The compound can be used in a variety of articles, including ophthalmic devices. Formula (I):

A macular health measurement and storage system comprises a plurality of macular-pigment measurement machine for measuring macular pigment density in humans, a plurality of computers each of which is associated with a corresponding one the macular-pigment measuring machines, and a central host. The plurality of macular-pigment measurement machines include a device for receiving macular pigment data from a patient, at least one data transfer port, and at least one processor that enables the transfer of the macular pigment data from the transfer port. The plurality of computers include a first port coupled to the data transfer port of the corresponding macular-pigment measurement machine for receiving the macular pigment data. Each of the computers includes a second port for transferring patient data. The central host is coupled to the second ports on each of the plurality of computers. The central host includes a storage device for storing the patient data.

Described are visible light absorbing compounds. The compounds have a visible light absorption maximum between 430 and 480 nm and a full width half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and up to 100 nanometers, wherein the compounds are photostable. The compounds substantially mimic the visible light absorbance properties of macular pigment while remaining photostable. The compounds may be used in a variety of articles, including ophthalmic devices.

To provide an oral composition for alleviating eye disorders.SOLUTION: An oral composition containing α - lipoic acid, an oral composition containing lutein and α - lipoic acid, a composition for improving the flavor of lutein, and an oral composition containing lutein and seaberry are prepared. Further, a method for improving the flavor of lutein and a method for improving the aggregation of lipoic acid are also provided. The oral composition containing α - lipoic acid is, for example, an oral composition for maintaining the amount of pigment in the macular region of the eye, maintaining the visual power, improving the contrast sensitivity of the eye, improving the focus adjustment of the eye, alleviating eye trouble, improving the condition of the eye, alleviating eye fatigue, improving accommodation failure, protecting the eye from light stimulation, or taking measures against blue light and liquid crystal light.SELECTED DRAWING: None